1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of autoimmunity. 2020;109:102433.
2. Sohrabi C, Alsafi Z, O'neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). International journal of surgery. 2020;76:71-6.
3. Alsharif W, Qurashi A. Effectiveness of COVID-19 diagnosis and management tools: A review. Radiography. 2021;27(2):682-7.
4. Sharma A, Ahmad Farouk I, Lal SK. COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention. Viruses. 2021;13(2).
5. Rai P, Kumar BK, Deekshit VK, Karunasagar I, Karunasagar I. Detection technologies and recent developments in the diagnosis of COVID-19 infection. Applied Microbiol Biotechnol. 2021;105(2):441-55.
6. Singh H, Chauhan P, Singh J, Saurabh, Gautam C, Kakkar AK. Concomitant use of dexamethasone and tetracyclines: a potential therapeutic option for the management of severe COVID-19 infection? Expert Review of Clinical Pharmacology. 2021;14(3):315-22.
7. Malek AE, Granwehr BP, Kontoyiannis DP. Doxycycline as a potential partner of COVID-19 therapies. IDCases. 2020;21:e00864.
8. Al-Kuraishy HM, Al-Gareeb AI, Alqarni M, Cruz-Martins N, El-Saber Batiha G. Pleiotropic effects of tetracyclines in the management of COVID-19: emerging perspectives. Frontiers in pharmacology. 2021;12:642822.
9. Alam MM, Mahmud S, Rahman MM, Simpson J, Aggarwal S, Ahmed Z. Clinical Outcomes of Early Treatment With Doxycycline for 89 High-Risk COVID-19 Patients in Long-Term Care Facilities in New York. Cureus. 2020;12(8):e9658.
10. Sodhi M, Etminan M. Therapeutic Potential for Tetracyclines in the Treatment of COVID-19. Pharmacotherapy. 2020;40(5):487-8.
11. Al-Kuraishy HM, Al-Gareeb AI, Alqarni M, Cruz-Martins N, El-Saber Batiha G. Pleiotropic Effects of Tetracyclines in the Management of COVID-19: Emerging Perspectives. Frontiers in pharmacology. 2021;12:642822.
12. Byrne JD, Shakur R, Collins JE, Becker S, Young CC, Boyce H, et al. Prophylaxis with tetracyclines in ards: Potential therapy for covid-19-induced ards? medRxiv. 2020:2020.07. 22.20154542.
13. Fredeking TM, Zavala-Castro JE, González-Martínez P, Moguel-Rodríguez W, Sanchez EC, Foster MJ, et al. Dengue Patients Treated with Doxycycline Showed Lower Mortality Associated to a Reduction in IL-6 and TNF Levels. Recent Patents on Anti-Infective Drug Discovery .2015;10(1):51-8.
14. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. The Journal of the American Medical Association. 2020;323(11):1061-9.
15. Castro JEZ, Vado-Solis I, Perez-Osorio C, Fredeking TM. Modulation of cytokine and cytokine receptor/antagonist by treatment with doxycycline and tetracycline in patients with dengue fever. Journal of Immunology Research. 2011;2011(1):370872.
16. Di Caprio R, Lembo S, Di Costanzo L, Balato A, Monfrecola G. Anti‐inflammatory properties of low and high doxycycline doses: an in vitro study. Mediators of inflammation. 2015;2015(1):329418.
17. Masters PS. The molecular biology of coronaviruses. Advances in virus research. 2006;66:193-292
